

Cipaglucoisidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study subgroup analyses

Barry Byrne,¹ Drago Bratkovic,² Jordi Díaz-Manera,³ Pascal Laforêt,⁴ Tahseen Mozaffar,⁵ Ans van der Ploeg,⁶ Mark Roberts,⁷ Benedikt Schoser,⁸ Antonio Toscano,⁹ Hai Jiang,¹⁰ Sheela Sitaraman Das,¹⁰ Mitchell Goldman,¹⁰ Jeff Castelli,¹⁰ Priya S. Kishani¹¹ on behalf of the PROPEL study group

¹University of Florida, Gainesville, FL, USA; ²PARC Research Clinic, Royal Adelaide Hospital, Adelaide, SA, Australia; ³John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle upon Tyne, UK; ⁴Raymond-Poincaré Hospital, Garches, France; ⁵University of California, Irvine, CA, USA; ⁶Erasmus MC University Medical Center, Rotterdam, the Netherlands; ⁷Salford Royal NHS Foundation Trust, Salford, UK; ⁸Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany; ⁹Università di Messina, Messina, Italy; ¹⁰Amicus Therapeutics, Inc., Philadelphia, PA, USA; ¹¹Duke University Medical Center, Durham, NC, USA

OBJECTIVE


- PROPEL (NCT03729362) is a Phase III, randomized, double-blind, active-controlled trial to assess the efficacy and safety of cipaglucoisidase alfa/miglustat in adults with late-onset Pompe disease (LOPD) compared with alglucosidase alfa/placebo.¹
- We report prespecified and *post hoc* subgroup analyses based on enzyme replacement therapy (ERT) status, baseline 6-minute walk distance (6MWD), and baseline percent predicted sitting forced vital capacity (FVC).

INTRODUCTION

- Pompe disease is a rare, autosomal recessive lysosomal disorder caused by pathogenic variants of the acid alpha-glucosidase (GAA) gene.²
- ERT with the recombinant human GAA (rhGAA), alglucosidase alfa, is the only approved treatment shown to improve prognosis in patients with infantile-onset Pompe disease (IOPD) and LOPD.^{3,4}
- Cipaglucoisidase alfa/miglustat is an investigational, two-component therapy comprising cipaglucoisidase alfa administered in conjunction with miglustat⁵
 - Cipaglucoisidase alfa is an rhGAA with enhanced glycosylation designed for improved uptake and processing
 - Miglustat is a small molecule that stabilizes cipaglucoisidase alfa in blood and enhances delivery of the active enzyme to tissues.

METHODS

Figure 1. PROPEL study design¹



*Two patients were randomized but not dosed; ¹195 mg for patients weighing 40–50 kg; ¹Baseline values were measured during screening (up to 30 days before dosing). For 6MWD and FVC, the baseline value was the average of the last two measurements obtained on or prior to first dose date. CFBL, change from baseline; IV, intravenous; Q2W, every 2 weeks; R, randomization.

Statistical methodology

- One ERT-naïve patient (alglucosidase alfa/placebo group), deemed clinically implausible by the principal investigator based on baseline assessments, was excluded from all efficacy analyses.
- Additional statistical methodology is available in the Supplement, which is accessible via the QR code.

RESULTS

Patients

- Of the 85 patients randomized to cipaglucoisidase alfa/miglustat, 80 completed the study; of the 38 patients randomized to alglucosidase alfa/placebo, 37 completed the study.
- Patient demographics at baseline were representative of the population and generally similar in the two treatment arms (Table 1).

Primary endpoint and first key secondary endpoint

- Overall, patients treated with cipaglucoisidase alfa/miglustat showed improvement over time in 6MWD and stabilization over time in FVC in comparison with those treated with alglucosidase alfa/placebo (Figure 2)
 - 6MWD showed greater improvement with cipaglucoisidase alfa/miglustat versus alglucosidase alfa/placebo but did not reach statistical superiority ($P=0.071$; Figure 2A)
 - FVC demonstrated a nominally statistically significant and clinically meaningful improvement with cipaglucoisidase alfa/miglustat versus alglucosidase alfa/placebo (nominal $P=0.023$; Figure 2B).


This study was supported by Amicus Therapeutics, Inc.

Table 1. Baseline characteristics

	Cipaglucoisidase alfa/miglustat n=85	Alglucosidase alfa/placebo n=38	Total N=123
Median (range) age, years	48.0 (19–74)	46.0 (22–66)	47.0 (19–74)
Male	36 (42.4)	20 (52.6)	56 (45.5)
Female	49 (57.6)	18 (47.4)	67 (54.5)
ERT-naïve	20 (23.5)	8 (21.1)	28 (22.8)
ERT-experienced	65 (76.5)	30 (78.9)	95 (77.2)
Median (range) previous ERT duration, years, ERT experienced only	7.6 (2.0–13.7)	7.1 (2.1–13.2)	7.4 (2.0–13.7)
Prespecified baseline 6MWD, n (%)			
≥75–<150 m	4 (4.7)	4 (10.5)	8 (6.5)
≥150–<400 m	55 (64.7)	22 (57.9)	77 (62.6)
≥400 m	26 (30.6)	12 (31.6)	38 (30.9)

Data are n (%) unless indicated.

Figure 2. Change from baseline in (A) 6MWD and (B) FVC in the overall population (n=122)




CFBL is mean (SE) LOCF. 6MWD data were not normally distributed and the 6MWD P value is from non-parametric ANCOVA; 6MWD parametric MMRM $P=0.097$. FVC data were normally distributed and the P value is from ANCOVA. Since the primary endpoint did not meet statistical significance, subsequent analyses of key secondary endpoints that were tested according to the hierarchy of the statistical analysis plan are interpreted as nominal statistical assessments of superiority. ANCOVA, analysis of covariance; LOCF, last observation carried forward; MMRM, mixed-effect model for repeated measures; SE, standard error.

Prespecified subgroup analyses

1. ERT status

- In the ERT-experienced population, 6MWD and FVC showed a nominally statistically significant and clinically meaningful improvement at week 52 with cipaglucoisidase alfa/miglustat versus alglucosidase alfa/placebo (nominal $P<0.05$ for both; Figure 3).
- In the smaller ERT-naïve population ($n=27$), variability was greater and 6MWD and FVC both numerically favored alglucosidase alfa/placebo
 - 6MWD: both the cipaglucoisidase alfa/miglustat ($n=20$) and alglucosidase alfa/placebo ($n=7$) groups had similar improvements over time (mean [SE] CFBL to week 52: +33.4 [10.9] m and +38.3 [11.1] m, respectively; nominal two-sided $P=0.60$)
 - FVC: both the cipaglucoisidase alfa/miglustat ($n=20$) and alglucosidase alfa/placebo ($n=7$) groups declined over time (mean [SE] CFBL to week 52: -4.1 [1.5] % and -3.6 [1.8] %, respectively; nominal two-sided $P=0.57$).

Figure 3. Change from baseline in (A) 6MWD and (B) FVC in ERT-experienced patients (n=95)




6MWD data were not normally distributed and the 6MWD P value is from non-parametric ANCOVA; 6MWD parametric MMRM $P=0.078$. FVC data were normally distributed and the FVC P value is from ANCOVA.

2. Baseline 6MWD categories

- Cipaglucoisidase alfa/miglustat was favored across prespecified baseline 6MWD categories versus alglucosidase alfa/placebo (Figure 4).

Figure 4. Change from baseline in 6MWD by prespecified baseline 6MWD categories in the overall population (n=122)




CFBL is mean (SE) LOCF (SE) to week 52.

Post hoc subgroup analyses

Baseline 6MWD and FVC categories

- Outcomes consistently favored cipaglucoisidase alfa/miglustat in the overall and ERT-experienced populations in patients with baseline 6MWD of <300 m and ≥300 m, and FVC of <55% and ≥55% (Figure 5).
- ERT-naïve population ($n=27$): three patients had a baseline 6MWD of <300 m and three had a baseline FVC of <55%; analyses of CFBL were not performed in these subgroups owing to the small patient numbers
 - Baseline 6MWD ≥300 m: both the cipaglucoisidase alfa/miglustat ($n=18$) and alglucosidase alfa/placebo ($n=6$) groups had similar improvements over time (mean [SE] CFBL to week 52: +34.4 [12.1] m and +30.8 [9.6] m, respectively)
 - Baseline FVC ≥55%: both the cipaglucoisidase alfa/miglustat ($n=19$) and alglucosidase alfa/placebo ($n=5$) groups declined over time (mean [SE] CFBL to week 52: -3.7 [1.5] % and -3.3 [2.6] %, respectively).

Figure 5. Change from baseline in 6MWD and FVC by baseline status in (A) the overall population (n=122) and (B) ERT-experienced patients (n=95)



CFBL is mean (SE) LOCF (SE) to week 52.

Safety summary

- The safety profile was similar for cipaglucoisidase alfa/miglustat and alglucosidase alfa/placebo (Table 2); further characterization of the safety profile is available in Supplementary Table 1.

Table 2. Safety summary

	Cipaglucoisidase alfa/miglustat n=85	Alglucosidase alfa/placebo n=38
TEAEs, n (%)	81 (95.3)	37 (97.4)
TEAEs potentially related to treatment	26 (30.6)	14 (36.8)
Serious TEAEs	8 (9.4)	1 (2.6)
Serious TEAEs potentially related to treatment	1 (1.2)*	0
TEAEs leading to study withdrawal	3 (3.5) [†]	1 (2.6) [†]
TEAEs leading to death	0	0
IARs	21 (24.7)	10 (26.3)

*IAR of anaphylactic reaction; [†]COVID-19-related pneumonia and IARs of anaphylactic reaction and chills; [†]Stroke, unrelated to treatment. IAR, infusion-associated reaction; TEAE, treatment-emergent adverse event.

CONCLUSIONS

- In the overall study population including ERT-naïve and ERT-experienced patients, cipaglucoisidase alfa/miglustat showed positive trends or clinically meaningful improvements on motor and respiratory functions compared with approved ERT, regardless of baseline 6MWD and % FVC assessments, and across both prespecified and *post hoc* subgroup analyses.
- Cipaglucoisidase alfa/miglustat demonstrated a similar safety profile to that of alglucosidase alfa/placebo.

Acknowledgments

We thank the patients, their families, and Pompe disease patient organizations for their participation in the PROPEL study. We also thank the investigators and site staff for their support and contribution to the PROPEL study.

The PROPEL study was funded by Amicus Therapeutics, Inc. Medical writing support was provided by Adam Gill, MRes, at Cence (an AMICUM™ agency), funded by Amicus Therapeutics, Inc. Some of the primary PROPEL data presented here were previously presented at the 17th Annual WORLDSymposium™, February 7–12, 2021, the 2021 MDA Virtual Clinical & Scientific Conference, March 15–18, 2021, the ICMVD Virtual Congress, May 21–22 and 28–29, 2021, and have been published.¹ Figures reprinted from *The Lancet*, Schoser B et al. Copyright © 2021, with permission from Elsevier. This presentation shares information about Amicus Therapeutics' investigational therapy, cipaglucoisidase alfa/miglustat, which is in development for the treatment of Pompe disease. This investigational therapy is not approved by any regulatory agency at this time. The presenter, Dr Barry Byrne, has no conflicts of interest to declare.

References

- Schoser B et al. *Lancet Neurol* 2021;20:1027–37.
- Kishani PS et al. *J Pediatr* 2020;144:535–43.
- Lumizyme (prescribing information). Sanofi Genzyme; 2020.
- Do HV et al. *Ann Transl Med* 2019;7:291.
- Xu S et al. *JCI Insight* 2020;4:e153338.
- ClinicalTrials.gov. NCT03729362. Available at: <https://clinicaltrials.gov/ct2/show/NCT03729362>

Poster PDF



Supplement



Please scan these quick response (QR) codes with your smartphone camera or app to obtain PDF copies of this poster and its supplementary material. Copies of materials obtained through QR codes are for personal use only and may not be reproduced without permission from WORLDSymposium™ and the authors of this poster.